Skip to main content
. 2008 Aug 22;3(4):244–250. doi: 10.1159/000149099

Table 1.

EBCTCG data for approximation of chemotherapy benefit in patients under 50 years with primary breast cancer [22]

Treatment HR recurrence years 0–4 HR breast cancer mortality
CMF vs. no CT 0.56 (0.05) 0.68 (0.05)
Anthracyclines vs. CMF 0.84 (0.05) 0.81 (0.05)
Taxanes vs. anthracyclines 0.84 (0.04) 0.86 (0.05)
Taxanes vs. no CI (multiplication of 3 RRs) 0.38 (0.07) 0.46 (0.08)
2p < 0.00001 2p < 0.00001

RR = Relative risk.